Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force-Reference-Cited by-同舟云学术

Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force

Published:2013-07 Issue:4 Volume:9 Page:438-444
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Vellas Bruno¹²³,Carrillo Maria C.⁴,Sampaio Cristina⁵,Brashear H. Robert⁶,Siemers Eric⁷,Hampel Harald⁸,Schneider Lon S.⁹,Weiner Michael¹⁰,Doody Rachelle¹¹,Khachaturian Zaven¹²,Cedarbaum Jesse¹³,Grundman Michael¹⁴,Broich Karl¹⁵,Giacobini Ezio¹⁶,Dubois Bruno¹⁷,Sperling Reisa¹⁸,Wilcock Gordon K.¹⁹,Fox Nick²⁰,Scheltens Philip²¹,Touchon Jacques²²,Hendrix Suzanne²³,Andrieu Sandrine¹²³,Aisen Paul²⁴,

Affiliation:

1. UMR1027 InsermToulouseFrance

2. University of Toulouse IIIToulouseFrance

3. Gerontopole ToulouseToulouse University HospitalToulouseFrance

4. Alzheimer's AssociationChicagoILUSA

5. CHDI FoundationPrincetonNJUSA

6. Janssen AISouth San FranciscoCAUSA

7. Eli LillyIndianapolisINUSA

8. Department of PsychiatryGoethe UniversityFrankfurtGermany

9. University of Southern California Keck School of MedicineLos AngelesCAUSA

10. Center for Imaging of Neurodegenerative DiseaseVA Medical Center, University of California San FranciscoSan FranciscoCAUSA

11. Alzheimer's Disease and Memory Disorders CenterBaylor College of MedicineHoustonTXUSA

12. The Campaign to Prevent Alzheimer's Disease by 2020PotomacMDUSA

13. Bristol‐Myers SquibbWallingfordCTUSA

14. Global R&D Partners, LLCSan DiegoCAUSA

15. Federal Institute of Drugs and Medical DevicesBonnGermany

16. Department of Internal Medicine, Rehabilitation and GeriatricsUniversity of GenevaGenevaSwitzerland

17. Institute for Memory and Alzheimer's DiseaseUMR‐S975, Salpêtrière Hospital, Pierre & Marie Curie UniversityParisFrance

18. Brigham and Women's HospitalHarvard Medical SchoolBostonMAUSA

19. University of OxfordOxfordUK

20. Dementia Research CentreUCL Institute of NeurologyLondonUK

21. Department of Neurology and Alzheimer CenterVU University Medical CentreAmsterdamNetherlands

22. University Hospital of MontpellierMontepellierFrance

23. Pentara CorporationSalt Lake CityUTUSA

24. Department of NeurosciencesUniversity of California, San DiegoSan DiegoCAUSA

Funder

Katharina-Hardt-Foundation, Bad Homburg, Germany

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2013.03.007

Reference20 articles.

1. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

2. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

4. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

5. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative Discoveries in Neurosurgical Treatment of Neurodegenerative Diseases: A Narrative Review;Current Alzheimer Research;2023-06

2. Commentary: Future of Alzheimer’s Disease Treatment: Combination Therapy and Precision Medicine;The Journal of Prevention of Alzheimer's Disease;2023

3. Neuroimaging Biomarkers in Alzheimer’s Disease and Related Disorders;Biomarkers in Neuropsychiatry;2023

4. Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective;Neurotherapeutics;2022-09

5. A Historical Review of Brain Drug Delivery;Pharmaceutics;2022-06-16